Estimating Real Prices of Medicines used in Hospitals

Study protocol

Commissioned by the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection
Estimating Real Prices of Medicines used in Hospitals

Modelling Discounts and Rebates based on experts' estimates

Study protocol

Authors:
Sabine Vogler
Peter Schneider
Nina Zimmermann

Project assistant:
Ingrid Freiberger

The views expressed in this publication are those of the authors and not necessarily of the commissioning institution.

Vienna, October 2019
Commissioned by the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection
How to cite: Vogler, Sabine; Schneider, Peter; Zimmermann, Nina (2019): Estimating Real Prices of Medicines used in Hospitals – Modelling Discounts and Rebates based on experts' estimates. Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna

ZI. P4/33/5121

Owner, editor and publisher: Gesundheit Österreich GmbH (Austrian Public Health Institute), Stubenring 6, 1010 Vienna, tel. +43 1 515 61, websites: www.goeg.at and http://ppri.goeg.at

For the environment:
This report is produced on recycled paper without optical brighteners.
Summary

Gesundheit Österreich GmbH (GÖG) was commissioned by the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (BMASGK) to conduct a European price comparison of medicines used in hospitals that takes "real prices" into account.

The present study protocol describes the methods for this study. Data collection is based on a survey among procurement experts about their opinion what discounts would be attainable for selected medicines used in hospitals. Their estimates will be used as input to model real prices in hospitals.

Key words

Medicine prices, hospital, European price comparison, discount, transparency, confidentiality

Acknowledgments

In January 2019, key elements of the methodology were presented to the GÖG Scientific Advisory Board. Some members agreed to review the proposed methodology according to scientific standards. Elements of the methodology were presented in meetings with members of the Informal Advisory Group (January 2019) and the “Sounding Board” (hospital owners representatives, March 2019). This study protocol is a revised version of a first draft on the planned methods published in April/May 2019. It has taken into consideration the comments from the GÖG Scientific Advisory Board, international researchers, the Informal Advisory Group of Hospital Pharmacists, the “Sounding Board” and the Association of the Pharmaceutical in Austria which GÖG has received during the consultation phase.
Content

Summary ................................................................................................................................................. III
Acknowledgments ................................................................................................................................... III
Figures and Tables ................................................................................................................................. V
Abbreviations ......................................................................................................................................... VI
1 Background .......................................................................................................................................... 7
2 Objectives of the study ........................................................................................................................ 8
3 Project organisation ............................................................................................................................ 9
4 Methodology ....................................................................................................................................... 10
  4.1 Survey method .............................................................................................................................. 10
  4.2 Methods related to analysis ............................................................................................................. 12
5 Time–line ........................................................................................................................................... 13
6 Appendix ............................................................................................................................................ 15
  6.1 Studies on real prices and discounts ............................................................................................ 15
  6.2 Proposal for medicines to be selected in the study ................................................................. 17
7 References ........................................................................................................................................... 20
Figures and Tables

Figure 5.1: Time schedule for the study ................................................................. 14

Table 3.1: Key actors in the context of the study ...................................................... 9

Table 6.1: Proposal for the selection of medicines for this price study: 30 active substances with 52 medicines ranked according to medicine groups (high, medium, low) and alphabetically according to the active substance name. ............................................. 17
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMNOG</td>
<td>Gesetz zur Neuordnung des Arzneimittelmarktes / Act on the Reform of the Market for Medicinal Products (Germany)</td>
</tr>
<tr>
<td>BMASGK</td>
<td>Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumenschutz / Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (Austria)</td>
</tr>
<tr>
<td>BMGF</td>
<td>Bundesministerium für Gesundheit und Frauen / Federal Ministry of Health and Women’s Affairs (Austria, previous name of the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection)</td>
</tr>
<tr>
<td>ECB</td>
<td>European Central Bank</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>GÖG</td>
<td>Gesundheit Österreich GmbH / Austrian Public Health Institute</td>
</tr>
<tr>
<td>HAI</td>
<td>Health Action International</td>
</tr>
<tr>
<td>MEA</td>
<td>Managed Entry Agreement</td>
</tr>
<tr>
<td>PHIS</td>
<td>Pharmaceutical Health Information System</td>
</tr>
<tr>
<td>PPI</td>
<td>Pharmaceutical Price Information (medicine price information service provided by GÖG)</td>
</tr>
<tr>
<td>PPRI</td>
<td>Pharmaceutical Pricing and Reimbursement Information</td>
</tr>
<tr>
<td>PPP</td>
<td>Pharmacy purchasing price</td>
</tr>
<tr>
<td>PRP</td>
<td>Pharmacy retail price</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>VAT</td>
<td>Value added tax</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
1 Background

The continuous monitoring and regular analysis of medicine prices support policy-makers in the development of pharmaceutical pricing policies. As one of its legally defined tasks, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute) is mandated to perform medicine price analyses.

There is need for estimating real prices in the inpatient sector:

- Many of the high-priced medicines that have increasingly entered the market in recent years are used either exclusively or primarily in hospitals (Vogler et al. 2018).

- Medicine procurement in the inpatient sector differs from that of the outpatient sector in many countries, including Austria. While outpatient medicine prices are the same throughout Austria, given the application of statutory (maximum) price regulation (Bundesministerium für Gesundheit und Frauen (BMGF) 2019) and price negotiation of the Main Association of Social Insurance Institutions, procurement of medicines in the inpatient sector is decentralised, performed by hospitals or owners of the hospitals (usually provinces). In most cases, those responsible for the procurement of medicines are in direct contact with the manufacturers and negotiate the prices for the hospital or hospitals of the same owner (Jommi 2018; Klemp et al. 2011; Morel et al. 2013; Pauwels et al. 2017; Stemar 2015; van Harten, Wim H et al. 2019).

- A large number of discounts and similar agreements (so-called managed entry agreements / MEA, such as price-volume agreements, risk-sharing agreements, capping) are applied in the inpatient sector (Ferrario/Kanavos 2013; Ferrario/Kanavos 2015). Due to the confidential nature of these discounts, the validity of international price comparisons based on list prices is limited.

A decade ago, commissioned by the European Commission and the Austrian Federal Ministry of Health, the research project “Pharmaceutical Health Information System” (PHIS) was conducted in order to gain knowledge about pharmaceutical provision and procurement in hospitals in Europe. For selected medicines in Austria and four other European countries, the real prices (in comparison to the published list prices) were collected and analysed as of September 2009. The PHIS study showed differences in the extent of discounts granted between studied countries and, in particular, between medicines: Whereas no discounts were granted for monopoly pharmaceuticals, medicines which, after hospitalisation, continued to be prescribed in the outpatient sector (as long-term therapy) achieved high discounts or were offered free of charge in some countries (Austria) (Vogler et al. 2010; Vogler et al. 2013a; Vogler et al. 2013b). Ten years later, the PHIS study is still one of the few research projects internationally that has investigated real prices and discounts in hospitals (see Appendix 1 for further information and results of the PHIS study and other relevant studies in this field).

Against this background, GÖG was commissioned to carry out a European price comparison of medicines used in hospitals in 2019, which considers “real prices” of medicines. This would add to previous price studies that were based on list prices (Schneider et al. 2018; Vogler et al. 2014;
Vogler et al. 2016). Following discussions with experts, a study protocol was developed and shared for peer and stakeholder review in April 2019. The comments GÖG received during the review pointed to some feasibility limitations of the originally planned methodology that had been informed by the data collection methods employed during the PHIS study. As a result, the methodology was adapted, and the study protocol has been accordingly revised.

2 Objectives of the study

The general objective of the study is to estimate “real prices” for medicines used in hospitals and to develop a model which considers discounts, rebates and similar price agreements without violating existing confidentiality agreements. The estimator aims to adjust for structural information e.g. countries, experience with procurement mechanisms. The inputs for the model will be collected from opinions of procurement experts in Austria and some other EU Member States.

The specific objectives of the study are:

» Definition of the concept of “price” (list price versus “real price” in the light of application of MEA) for medicines used in hospitals and an assessment as to whether and in what form these prices can be collected, calculated (ex-post) and analysed

» Survey among experts about their opinion which size of discounts they would expect in the next year for (selected) medicines in their respective country.

» Analysis of estimated “real prices” against the backdrop of the national pharmaceutical system

It is not an objective of this study to evaluate different procurement models in the inpatient sector with regard to their impact on medicine prices or access to medicines.

In addition, this study do not aim to collect and evaluate information on real prices, but to develop a statistical model of real prices based on expert inputs.

1 Regardless of the question about confidentiality, the design of a pricing model can be complex, making it difficult to determine the actual price.
3 Project organisation

Relevant actors of the study are summarised in Table 3.1.

Table 3.1: Key actors in the context of the study

<table>
<thead>
<tr>
<th>Actor</th>
<th>Role / Task</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austrian Federal Ministry of Labour, Social Affairs, Health and Consumer Protection</td>
<td>Commissioning party</td>
</tr>
<tr>
<td>Project team at GÖG</td>
<td>Implementation of the study</td>
</tr>
</tbody>
</table>
| “Sounding Board”: representatives of all key hospital owners (provinces, orders) in Austria, represented by the management, the central procurement department or hospital pharmacy | Feedback on the draft methodology, receipt of the study protocol, support through contacts to respondents, receipt of the study prior to publication (possibility to provide feedback)  
Presentation of the study and its methodology (study protocol) at a meeting in March 2019 and, if needed, another meeting in autumn 2019 to present the preliminary results |
| Informal expert group: selected hospital pharmacists in Austria       | Informal exchange on the study methodology, in particular on product selection, feedback on the study protocol, advance receipt of the study before publication (possibility to provide feedback)  
Information exchange at meetings in January and March 2019          |
| Scientific Advisory Board of GÖG: individual members                 | Informal exchange on the study methodology, feedback on the study protocol, receipt of the study before publication (possibility to provide feedback)  
Information exchange at a meeting in January 2019                    |
| Procurement experts, hospital pharmacists and other people affiliated with procurement in Austria and other countries | Possible experts for estimates for the selected countries (depending on the selected method, possibly different for the countries of the study)                                                                 |
| Researchers of other countries, international organisations, stakeholders | Reviewers who were invited to provide comment on the study protocol (available in German and English version)                                                                                  |
4 Methodology

4.1 Survey method

Type of price comparison:

» Survey among experts about their personal opinion which price reductions they would consider as attainable given their experience in their respective country and to develop an estimator for real prices

Justification: Due to contractual obligations hospitals or procurement organisations are not allowed to share information on real prices of specific medicines. Therefore procurement experts will be asked about their personal opinion what size of discount they would consider as attainable for defined medicines / medicine groups. Experts must not share real prices or existing discounts but their estimation what size of discounts they would expect to achieve in the next year.

Country and hospital selection:

» Austria and around 3–5 further European countries. The selection of countries will be finalised after having explored the availability of procurement experts in the countries (discussion with collaboration partners in the countries).

» It is aimed to survey experts in five hospitals per country (caveat: Denmark and Norway have one hospital price country-wide; in other countries prices of the hospitals of one owner can be the same as well. The selection of hospitals to be surveyed will be guided by the respective country contacts.

Justification: The selection criteria for this survey are (1) European countries with similar economic strength, (2) countries which had already been investigated in the 2009 PHIS study, and (3) differences in the characteristics of the organisation of the pharmaceutical system and medicine procurement in the inpatient sector. Eventually, the willingness of experts to participate and provide estimates is a pragmatic guiding principle.

Selection of products:

» Six medicines groups (on–patent biological medicines to treat cancer, on–patent medicines to treat orphan diseases, on–patent biological medicines to treat other diseases, on–patent chemical medicines, off–patent biological medicines, off–patent chemical medicines) with a representative selection of 5–6 medicines based on defined criteria (see below)

» guided by technical advice provided by an informal expert group

» provisional list of the 36 active ingredients; for further information see appendix 2 in chapter 6.2
**Justification:** Inclusion criteria for this study were (1) medicines with a high budget impact for the inpatient sector, (2) medicines of different indication groups, and (3) medicines which also account for high public expenditure in the outpatient sector (due to their price or quantity, e.g. long-term prescribing for outpatients following a first prescription in the hospital sector).

**Date of survey:**

- Expert input will be surveyed in Q4/2019
- Estimates on discounts for the next year (2020)
- Reference date of price data is 31 September 2019

**Justification:** If experts are asked about their opinion for attainable discounts there is a need for a benchmark to put their estimates in perspective. Therefore price data and estimates should be as updated as possible.

**Scope of the survey:**

- Data for the descriptive and quantitative analysis of reported expected value within the different group of medicines and over the whole sample
- Supplementary information – e.g. on background of the surveyed or the country characteristics in which the procurement experience is embedded – will be surveyed in order to adjust for in the regression.

**Justification:** Since the survey asks experts about their personal opinion, no specific calculation methods are necessary. However, the questionnaire will provide a common definition, in order to ensure comparability of subjectively assessment data. In addition, further data and background information on the setting in which the expert opinion is based will be collected used for the regression and – if necessary – in the sensitivity analyses.

**Survey method:**

- **Questionnaire:** For the expected price reduction of selected medicines: survey among procurement experts of the in-patient sector per country, by means of an online questionnaire.
- For further background information e.g. setting in which experience is embedded to construct estimators: part of the online survey
- Hospital list prices (ex-factory price or pharmacy purchasing price (PPP) in some countries) – are not part of the primary data collection, but will be retrieved from the GÖG Pharma Price Information (PPI) service

**Justification:** There is some literature which aim to estimate possible discounts levels (Morgan et al. 2017). Since no Information on real prices is publicly available and, primary data collection
needs to take confidential issues into account, experts’ estimates are considered as proxy input to run the regression.

**Confidentiality:**

» Confidentiality will be ensured for all participating experts that share their personal expectations as input to the statistical model.

» All results will be estimates on real prices and cannot be traced back to any individual institutions or countries. If deemed necessary, data presentation can be further aggregated over the defined medicines groups.

**Justification:** A method was developed that does not investigate specific hospitals as survey of discounts in real-world settings might be perceived in possible violation of contractual obligations.

**Comparator product**

» no comparator product, but consideration of the active ingredient

» consideration of generic and biosimilar medicines

**Justification:** The proposed method is not a medicine price comparison but aims to develop an estimator of possible “real” prices. Since it can be assumed that expectations on price reductions are uniformly over all authorised presentations of an active ingredient it is not necessary to define a comparator product. However, the definition of medicine groups including off-patent chemical and biological active ingredients allows to adjust the estimator for dynamics related to the off-patent life-cycle phase of medicines.

### 4.2 Methods related to analysis

**Analysis parameters:**

» Unit of the analysis: Expected price reductions over an active ingredient; in contrast to price comparisons an analysis of unit prices of comparator products is not relevant,

» Exchange rates: not relevant as, since the percentage size of discounts is applied to the respective price in national currency units and therefore translates into some form of Indexation:

» Weighting of prices: the effect of a countries’ income level is captured by the country fixed effects; economic indicators will be included in the regression to decompose the country effect
Evaluations and presentation of results:

» The descriptive analysis of the range of expected price reductions, adjusted for structural factors in which the experts’ opinion is embedded in, for each medicine group will be presented as a boxplot (see example below) or in another appropriate form

![Boxplot example](image)

» Construction of an estimator for real prices that includes structural and medicine-group specific variables which are included in the Vector \( (X_i) \)

\[
\text{ListPrice}_i = \alpha_i + \beta_i \text{RealPrice}_i + \gamma_i X_i + e
\]

» Following structural and medicine-group specific variables will be considered in the estimator: (1) Country effects, (2) Institutional background of the surveyee, (3) Therapeutic group effects, (4) Orphan designation,

5 Time–line

Figure 5.1 describes the time schedule and procedures for the study.
Figure 5.1: Time schedule for the study

- **Methodology development / Study protocol**: GÖG develops a methodology for the price study on hospital medicines taking into account knowledge of experts (e.g., informal expert group) (Dec ’18 - Mar. ’19)

- **Consultation and finalisation of methods**: The study protocols presented to the commissioning authority, the Sounding Board, and the information expert group. Austrian and international researchers will be invited for feedback. The study protocol will be finalised upon receipt of comments (Apr. ’19 - Sep. ’19)

- **Data Collection**: Expert inputs and further information will be collected according to the methods in Austria and the countries of the survey (Oct. ’19 - Dec. ’19)

- **Analysis and first draft**: An analysis is conducted and the results are presented in a first draft (Jan. ’20 - Feb. ’20)

- **Review**: The first draft is sent to the Sounding Board, the commissioning party, and other stakeholders for review. It is intended to also present the results to the Sounding Board at a meeting (Mar. ’20 - Apr. ’20)

- **Finalisation of the report and dissemination**: The scientific report will be completed and upon publication approval, published on the GÖG website. Results are disseminated to decision-makers and a scientific audience through presentations and scientific articles (May ’20 and Q4/2020)

Source: Gesundheit Österreich GmbH (GÖG)
6 Appendix

6.1 Studies on real prices and discounts

In total, there are only a few studies on real prices of medicines used in hospitals. In the following the results of some of the major studies will be presented.

**PHIS project – EU project on medicines management and prices in hospitals**

One focus of the PHIS project (PHIS = Pharmaceutical Pricing and Reimbursement Information) commissioned by the European Commission was a survey of the organization of the inpatient pharmaceutical system in the countries of the network (36 European countries) and a survey of hospital prices in five case study countries (Austria, Netherlands, Norway, Portugal, Slovakia). Prices (list prices and "real prices") for twelve medicines as of September 2009 were collected from a total of 25 hospitals.

The price survey showed differences in "real prices" and the extent of discounts between the case study countries. The highest median discounts were found in Norway, followed by the Netherlands. Study results suggested that higher discounts could be obtained with centralised than with decentralised procurement. In all countries surveyed, the patent status of the medicines examined had an effect on the level of discounts: whereas hospitals were usually not granted discounts for patent-protected medicines – predominantly cancer medicines – and had to pay the list price, medicines used as long-term therapy after a hospital stay in the outpatient sector tended to have high discounts (Vogler et al. 2010; Vogler et al. 2013b). In Austria, a pattern of extreme values was evident – either hospitals bought the medicines at list prices or they received them for free from the pharmaceutical companies (Vogler et al. 2013a).

The PHIS project carried out methodology work to provide a definition of "real prices" in view of different price and financing models, e.g. discounts, price-volume agreements, bundling with the purchase of other medicines or other products, or cost-free products (Vogler et al. 2010).

**Relevance of discount agreements and average amount of discounts**

In its European overview for 27 countries, the PHIS project also surveyed the relevance of discount arrangements (in numerous countries) and cost-free medicines (only a few countries besides Austria, e.g. Cyprus, Ireland, Slovakia) in the inpatient sector. Occasionally, countries also provided the average amount of discounts (Vogler et al. 2010).

A similar overview is provided by a study carried out in 2011 on the significance of discounts granted by the pharmaceutical industry to public payers, as well as their design and average amount. The study covered both the outpatient and the inpatient sectors; the information was provided by members of the PPRI (Pharmaceutical Pricing and Reimbursement Information) network (Vogler et al. 2012).
Real prices of cancer medicines

The study of van Harten, Wim H. et al. (2016) collected list and real prices of nine anti-cancer medicines in June/July 2015 using questionnaires in 21 hospitals in 15 countries. The study showed not only considerable differences in list prices (up to 92%) and real prices (58%) between countries, but also in the level of discounts. While Italy and Spain achieved discounts of 30 percent and more for some medicines, Central and Eastern European countries paid the list price for a number of the medicines studied (van Harten, Wim H. et al. 2016).

For some medicines, however, no real price data could be collected, as some interviewees were concerned about (legal) consequences and were not willing to provide price information from confidential agreements on medicines. Furthermore, the Belgian government pointed out that the real price communicated for Belgium was de facto even lower (De Block 2016). Despite these weaknesses, this study by van Harten, Wim H. et al. (2016) is one of the few scientific papers that published real prices for hospital medicines.

Study on access to medicines used in hospitals, including hospital prices

A study by Health Action International (HAI) investigated access to patented medicines in hospitals in four European countries (Austria, France, Latvia and Spain). The prices of selected medicines were analysed and the authors came to the conclusion that hospital prices do not seem to be related to the economic power of the countries. However, official list prices were used in this study because the real prices were not accessible. The lack of transparency of real prices was highlighted as an important limitation, and the recommendation was made that EU Member States should be obliged to disclose confidential discounts in a publicly accessible database (Hawlik/Devalière 2016).

Anonymous surveys on discounts

Morgan et al. (2017) collected the average amount of discounts in eleven economically strong countries in America, Europe and Australasia, but only for medicines in the outpatient sector. The discounts for both primary care medicines and specialised medicines were usually between 20 and 29 percent of the list price, with one third of respondents stating that they could obtain discounts of more than 60 percent on one or more medicines (Morgan et al. 2017). It is worth mentioning that in this study the data was already submitted to the researcher anonymously.

Review of literature on real prices

A systematic literature search came to the conclusion that hardly any studies on real prices are available in the published literature (Mardetko et al. 2018): Only five studies were found on the subject of “discounts”. In addition to the above-mentioned studies, these included a study on Germany in which an average price difference of approximately 22 percent (18 percent for medicines for rare diseases) was found between the price announced by the pharmaceutical manufacturer upon market authorisation and the price determined after price negotiations (Theidel/von
der Schulenburg 2016)², and a study on off-patent medicines in the pharmacy market. In this study, an average discount of 39.3 percent of the reimbursement price was observed for 179 generics, which pharmacies were able to obtain at purchase – with the possibility of higher discounts with a higher number of suppliers (Puig-Junoy 2012).

6.2 Proposal for medicines to be selected in the study

Table 6.1:
Proposal for the selection of medicines for this price study: 30 active substances with 52 medicines ranked according to medicine groups (high, medium, low)³ and alphabetically according to the active substance name.

<table>
<thead>
<tr>
<th>Active ingredient</th>
<th>ATC code</th>
<th>No. of authorised presentations</th>
<th>Further information on authorised presentations / Possible Names of Biosimilars</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>On-Patent biological medicines to treat cancer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>On-Patent biological medicines to treat other diseases</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

² However, the study did not take into account further individual discounts between companies and individual health insurance funds (“selective discount contracts”) or hospitals or hospital associations.

³ The development of medicines groups is based on the WHO/HAI methodology to survey medicine prices (WHO/HAI 2008) which recommends to establish medicines groups of different relevance (“core list” and further groups). Medicines included in the medicines group 1 should have high data availability.
<table>
<thead>
<tr>
<th>Active Ingredient</th>
<th>ATC code</th>
<th>No. of authorised presentations</th>
<th>Further information on authorised presentations / Possible Names of Biosimilars</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>On-Patent Medicines to treat Orphan diseases</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>On-Patent chemical medicines</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Off-Patent biological medicines</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>B01AB05</td>
<td>101</td>
<td>Lovenox/Clexane, Enoxaparin Becat, Enoxaparin Rovi, Hepaxane, Inhixa, Neoparín</td>
</tr>
<tr>
<td>Active ingredient</td>
<td>ATC code</td>
<td>No. of authorised presentations</td>
<td>Further information on authorised presentations / Possible Names of Biosimilars</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Filgrastim</td>
<td>L03AA02</td>
<td>12²</td>
<td>Accofil, Filgrastim HEXAL, Grastofil, Neupogen, Nivestim, Ratio-grastim, Tevegrastim, Zarzio</td>
</tr>
<tr>
<td>Infliximab</td>
<td>L04AB02</td>
<td>5²</td>
<td>Flixabi, Inflectra, Remicade Remsima, Zessly</td>
</tr>
<tr>
<td>Rituximab</td>
<td>L01XC02</td>
<td>4²</td>
<td>Blitzima, Mabthera, Ritemvia, Rixathon, Riximyo, Truxima</td>
</tr>
<tr>
<td>Pegfilgrastim</td>
<td>L03AA13</td>
<td>4²</td>
<td>Fulphila, Neulasta, Pelgraz, Pelmeg, Ziextenzo</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>L01XC03</td>
<td>2²</td>
<td>Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera</td>
</tr>
</tbody>
</table>

**Off-Patent chemical medicines**

<table>
<thead>
<tr>
<th>Active ingredient</th>
<th>ATC code</th>
<th>No. of authorised presentations</th>
<th>Further information on authorised presentations / Possible Names of Biosimilars</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipin</td>
<td>C08CA01</td>
<td>6¹</td>
<td></td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>B01AC04</td>
<td>3¹</td>
<td></td>
</tr>
<tr>
<td>Imatinib</td>
<td>L01XE01</td>
<td>16²</td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>L01CD01</td>
<td>2²</td>
<td></td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>A02BC02</td>
<td>2¹</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>C10AA07</td>
<td>6¹</td>
<td></td>
</tr>
</tbody>
</table>

ATC = Anatomical Therapeutic Chemical

¹ The number of authorised presentations refers to different strengths of the reference product according to the product monography

² The number of authorised presentations refer to the reference product

³ The number of authorised presentations refer to different strengths of the active ingredient available on the market

Source: Gesundheit Österreich GmbH, advised by hospital pharmacists, Presentation: Gesundheit Österreich GmbH
7 References

Bundesministerium für Gesundheit und Frauen (BMGF) (2019): Regelung für die Vorgehensweise der Preiskommission für die Ermittlung des EU Durchschnittspreises gemäß §§ 351c Abs. 6 und Abs. 9a ASVG, Fassung vom 21. 01. 2019

De Block, Maggie (2016): The difficulty of comparing drug prices between countries. In: The Lancet Oncology 17/4:e125

Ferrario, Alessandra; Kanavos, Panos (2013): Managed entry agreements for pharmaceuticals: The European experience. London School of Economics (LSE), London


Hawlik, K; Devalière, A (2016): Access to High–priced Medicines in Hospital Settings in Europe: A Study in Four European Countries. Amsterdam: Health Action International


Morel, Thomas; Arickx, F; Befrits, G; Siviero, PD; van der Meijden, CMJ; Xoxi, E; Simoens, Steven (2013): Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006–2012). In: Value in Health 16/7:A391–A391


Pauwels, Kim; Huys, Isabelle; Vogler, Sabine; Casteels, Minne; Simoens, Steven (2017): Managed Entry Agreements for oncology drugs: lessons from the European experience to inform the future. In: Frontiers in pharmacology 171/8:


Schneider, Peter; Vogler, Sabine; Zimmermann, Nina; Zuba, Martin (2018): Preisvergleich ausgabenstarker Arzneispezialitäten 2017. Hg. v. (BMASGK), Bundesministerium für Arbeit Soziales Gesundheit und Konsumentenschutz, Wien


Vogler, Sabine; Habl, Claudia; Leopold, Christine; Mazag, Jan; Morak, Simone; Zimmermann, Nina (2010): PHIS Hospital Pharma Report. Pharmaceutical Health Information System (PHIS), Vienna


Vogler, Sabine; Schneider, Peter; Zimmermann, Nina (2016): Preisvergleich kostenintensiver Arzneimittel 2015 (Wissenschaftlicher Endbericht). Gesundheit Österreich GmbH, Wien


Vogler, Sabine; Zimmermann, Nina; Habl, Claudia; Mazag, Jan (2013a): The role of discounts and loss leaders in medicine procurement in Austrian hospitals – a primary survey of official and actual medicine prices. In: Cost Effectiveness and Resource Allocation 11/1:15

Vogler, Sabine; Zimmermann, Nina; Habl, Claudia; Piessnegger, Jutta; Bucsics, Anna (2012): Discounts and rebates granted to public payers for medicines in European countries. In: Southern Med Review 5/1:38–46

Vogler, Sabine; Zimmermann, Nina; Leopold, Christine; Habl, Claudia; Mazag, Jan (2013b): Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries. In: The Open Pharmacoeconomics & Health Economics Journal 5/1:1–10